These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37900719)

  • 1. Cognitive Impairment and Risk Factors in Post-COVID-19 Hospitalized Patients.
    Khieukhajee J; Rojana-Udomsart A; Srisarakorn P; Wongsurit T; Aungsumart S
    Dement Geriatr Cogn Dis Extra; 2023; 13(1):18-27. PubMed ID: 37900719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Multidisciplinary Rehabilitation Enhanced with Neuropsychological Treatment on Post-Acute SARS-CoV-2 Cognitive Impairment (Brain Fog): An Observational Study.
    Rabaiotti P; Ciracì C; Donelli D; Oggioni C; Rizzi B; Savi F; Antonelli M; Rizzato M; Moderato L; Brambilla V; Ziveri V; Brambilla L; Bini M; Nouvenne A; Lazzeroni D
    Brain Sci; 2023 May; 13(5):. PubMed ID: 37239263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissipating the fog: Cognitive trajectories and risk factors 1 year after COVID-19 hospitalization.
    Gonçalves NG; Aliberti MJR; Bertola L; Avelino-Silva T; Dias MB; Apolinario D; Busatto G; Forlenza O; Nitrini R; Brucki SMD; Brunoni AR; Vidal KSM; Jacob-Filho W; Suemoto CK;
    Alzheimers Dement; 2023 Sep; 19(9):3771-3782. PubMed ID: 36861807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of "brain fog" 1 year after COVID-19 disease.
    Cristillo V; Pilotto A; Piccinelli SC; Gipponi S; Leonardi M; Bezzi M; Padovani A
    Neurol Sci; 2022 Oct; 43(10):5795-5797. PubMed ID: 35930181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients.
    Ermis U; Rust MI; Bungenberg J; Costa A; Dreher M; Balfanz P; Marx G; Wiesmann M; Reetz K; Tauber SC; Schulz JB
    Neurol Res Pract; 2021 Mar; 3(1):17. PubMed ID: 33712089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyposmia Is Associated with Reduced Cognitive Function in COVID-19: First Preliminary Results.
    Pirker-Kees A; Platho-Elwischger K; Hafner S; Redlich K; Baumgartner C
    Dement Geriatr Cogn Disord; 2021; 50(1):68-73. PubMed ID: 33853062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study.
    Hartung TJ; Neumann C; Bahmer T; Chaplinskaya-Sobol I; Endres M; Geritz J; Haeusler KG; Heuschmann PU; Hildesheim H; Hinz A; Hopff S; Horn A; Krawczak M; Krist L; Kudelka J; Lieb W; Maetzler C; Mehnert-Theuerkauf A; Montellano FA; Morbach C; Schmidt S; Schreiber S; Steigerwald F; Störk S; Maetzler W; Finke C
    EClinicalMedicine; 2022 Nov; 53():101651. PubMed ID: 36133318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Premorbid vulnerability and disease severity impact on Long-COVID cognitive impairment.
    Cristillo V; Pilotto A; Cotti Piccinelli S; Bonzi G; Canale A; Gipponi S; Bezzi M; Leonardi M; Padovani A;
    Aging Clin Exp Res; 2022 Jan; 34(1):257-260. PubMed ID: 35014002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidomain cognitive impairment in non-hospitalized patients with the post-COVID-19 syndrome: results from a prospective monocentric cohort.
    Schild AK; Goereci Y; Scharfenberg D; Klein K; Lülling J; Meiberth D; Schweitzer F; Stürmer S; Zeyen P; Sahin D; Fink GR; Jessen F; Franke C; Onur OA; Kessler J; Warnke C; Maier F
    J Neurol; 2023 Mar; 270(3):1215-1223. PubMed ID: 36422669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort.
    Del Brutto OH; Wu S; Mera RM; Costa AF; Recalde BY; Issa NP
    Eur J Neurol; 2021 Oct; 28(10):3245-3253. PubMed ID: 33576150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term cognitive dysfunction after the COVID-19 pandemic: a narrative review.
    Shariff S; Uwishema O; Mizero J; Devi Thambi V; Nazir A; Mahmoud A; Kaushik I; Khayat S; Yusif Maigoro A; Awde S; Al Maaz Z; Alwan I; Hijazi M; Wellington J; Soojin L
    Ann Med Surg (Lond); 2023 Nov; 85(11):5504-5510. PubMed ID: 37915705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for cognitive sequelae of SARS-CoV-2 infection: a comparison between the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA).
    Aiello EN; Fiabane E; Manera MR; Radici A; Grossi F; Ottonello M; Pain D; Pistarini C
    Neurol Sci; 2022 Jan; 43(1):81-84. PubMed ID: 34668124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychological functioning in post-ICU patients after severe COVID-19 infection: The role of cognitive reserve.
    Costas-Carrera A; Sánchez-Rodríguez MM; Cañizares S; Ojeda A; Martín-Villalba I; Primé-Tous M; Rodríguez-Rey MA; Segú X; Valdesoiro-Pulido F; Borras R; Peri JM; Vieta E
    Brain Behav Immun Health; 2022 May; 21():100425. PubMed ID: 35156065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of COVID-19 on cognition and mood after hospitalization and at 2-month follow-up.
    Peskar M; Šimunič B; Šlosar L; Pišot S; Teraž K; Gasparini M; Pišot R; Marusic U
    Front Psychol; 2023; 14():1141809. PubMed ID: 37303911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in cognitive functioning after COVID-19: A systematic review and meta-analysis.
    Crivelli L; Palmer K; Calandri I; Guekht A; Beghi E; Carroll W; Frontera J; García-Azorín D; Westenberg E; Winkler AS; Mangialasche F; Allegri RF; Kivipelto M
    Alzheimers Dement; 2022 May; 18(5):1047-1066. PubMed ID: 35297561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognitive screening in patients following SARS-CoV-2 infection: tools for triage.
    Blackmon K; Day GS; Powers HR; Bosch W; Prabhakaran D; Woolston D; Pedraza O
    BMC Neurol; 2022 Jul; 22(1):285. PubMed ID: 35907815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional connectivity underlying cognitive and psychiatric symptoms in post-COVID-19 syndrome: is anosognosia a key determinant?
    Voruz P; Cionca A; Jacot de Alcântara I; Nuber-Champier A; Allali G; Benzakour L; Thomasson M; Lalive PH; Lövblad KO; Braillard O; Nehme M; Coen M; Serratrice J; Pugin J; Guessous I; Landis BN; Adler D; Griffa A; Van De Ville D; Assal F; Péron JA
    Brain Commun; 2022; 4(2):fcac057. PubMed ID: 35350554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection.
    Antar AAR; Yu T; Demko ZO; Hu C; Tornheim JA; Blair PW; Thomas DL; Manabe YC
    Front Immunol; 2023; 14():1147549. PubMed ID: 37187756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.